Director-affiliated fund invests $1.16M in private placement, increasing stake to 6.9%
CALC has more than doubled off its 52-week low of $0.461 on light trading volume (0.3× avg).
Summary
A fund affiliated with director Evgeny Zaytsev invested $1.16 million in CalciMedica's private placement, boosting its stake to 6.9% and providing significant capital.
Key Events · Ownership and Investor Activity · CALC
-
Significant Investment
Bering Partners II, an entity affiliated with director Evgeny Zaytsev, purchased 1,450,267 shares for $1,164,999.48 in a private placement.
-
Increased Ownership Stake
This investment increases Bering Partners II's beneficial ownership to 2,113,513 shares, representing 6.9% of CalciMedica's common stock.
-
Warrant Rights Included
The purchase includes rights to receive Series A and Series B warrants upon stockholder approval, with exercise prices of $0.8033 and $1.00 respectively.
-
Beneficial Ownership Limit Raised
The beneficial ownership limitation for an existing warrant held by Bering II was increased to 19.99% on July 2, 2026, indicating potential for further share acquisition.
Analysis · CALC · Life Sciences
Bering Partners II, an investment entity affiliated with director Evgeny Zaytsev, made a substantial investment of $1.16 million in CalciMedica's recent private placement. This purchase, representing 7.64% of the company's market capitalization, increases their beneficial ownership to 6.9% and includes rights to receive additional warrants. This significant capital infusion from a director-affiliated entity provides crucial funding and signals confidence following recent positive clinical trial results and a prior loan amendment.
At the time of this filing, CALC was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.3M. The 52-week trading range was $0.46 to $7.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.